Meletios A. Dimopoulos, MD, on the Phase III BOSTON Study in Multiple Myeloma
Meletios A. Dimopoulos, MD, discussed the phase III Boston study examining a new combination therapy to treat patients with multiple myeloma who have received 1 to 3 prior therapies.
Meletios A. Dimopoulos, MD, discussed the phase III Boston study presented at the 2020 ASCO Virtual Scientific Program examining a new combination therapy to treat patients with multiple myeloma who have received 1 to 3 prior therapies.
Transcription:
We have a new triplet—selinexor (Xpovio), bortezomib (Velcade), and dexamethasone—which could be administered for patients who have received 1 to 3 prior lines of therapy. It could be 1 of the treatments that could be used for patients who have been exposed and progress on lenalidomide (Revlimid) maintenance or continuous treatment. I believe it is an additional combination for the treatment of myeloma patients.
It gives another combination. For example, whenever we have patients who progressed on lenalidomide, often times we use a pomalidomide-based regimen. In this case, we could change completely the mode of action, move to a combination that is not including anemic, and then maybe use pomalidomide (Pomalyst) later on.
![“Every patient [with multiple myeloma] should be offered CAR T before they’re offered a bispecific, with some rare exceptions,” said Barry Paul, MD.](/_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fcancernetwork%2F70a5f0fed7009863fe30cf0740cf32014ebaf5be-2974x1660.png%3Ffit%3Dcrop%26auto%3Dformat&w=3840&q=30 "“Every patient [with multiple myeloma] should be offered CAR T before they’re offered a bispecific, with some rare exceptions,” said Barry Paul, MD.")
Navigating AE Management for Cellular Therapy Across Hematologic Cancers
A panel of clinical pharmacists discussed strategies for mitigating toxicities across different multiple myeloma, lymphoma, and leukemia populations.
